Top Small Cap Losers: BDTX, MRUS, HOOK
4:06 pm Thursday, May 20th, 2021
Black Diamond Therapeutics Inc (NASDAQ: BDTX) slumped over 40% by day trading to $13.29 after the company announced initial data from the Phase 1 dose-escalation portion of its MasterKey-01 trial of BDTX-189 in patients with advanced solid tumors harboring certain oncogenic alterations; co states that the data, which will be presented at the ASCO Annual Meeting in June, provides “evidence of anti-cancer activity and a safety profile that is in-line with [co’s] preclinical expectations”; drug-related adverse events observed included medically manageable gastrointestinal events. At record lows.
Merus NV (NASDAQ:MRUS) is down 14.75% at $21.50 after the company announced the publication of an abstract highlighting interim data from its Phase 1/2 eNRGY trial and Early Access Program of zenocutuzumab in patients with NRG1+ cancers in connection with the upcoming ASCO Annual Meeting. Among findings, of 33 patients treated with Zeno who were evaluable for response, tumor regression was observed in 25 of 33 patients, with confirmed partial response in 9 of 33.
Hookipa Pharma Inc (NASDAQ: HOOK) slide 15.31% to $16.12 as the company announced that it will present the first data on HB-201/HB-202 alternating 2-vector therapy and expanded HB-201 data at the ASCO Annual Meeting; the abstract for co’s presentation is available online.
